Impact of guselkumab, an interleukin-23 p19 subunit inhibitor, on enthesitis and dactylitis in patients with moderate to severe psoriatic arthritis: results from a randomised, placebo-controlled, phase II study by Mease, PJ et al.
ORIGINAL RESEARCH
Impact of guselkumab, an interleukin-23
p19 subunit inhibitor, on enthesitis and
dactylitis in patients with moderate to
severe psoriatic arthritis: results from
a randomised, placebo-controlled, phase
II study
Philip J Mease ,1,2 Dafna D Gladman ,3 Atul Deodhar,4 Dennis G McGonagle,5
Peter Nash,6 Wolf-Henning Boehncke,7 Alice Gottlieb,8 Xie L Xu,9 Stephen Xu,10
Elizabeth C Hsia,10,11 Chetan S Karyekar,12 Philip S Helliwell 13
ABSTRACT
Objective To evaluate the effect of guselkumab on
enthesitis and dactylitis in a phase II trial of patients with
active psoriatic arthritis (PsA).
Methods This was a phase II, randomised, placebo-
controlled, double-blind trial of adults with active PsA (≥3
swollen and ≥3 tender joints and C reactive protein ≥0.3 mg/
dL) despite conventional synthetic disease-modifying anti-
rheumatic drug, non-steroidal anti-inflammatory drug, and/
or oral corticosteroid therapy. Patients were randomised to
subcutaneous injections of guselkumab 100 mg or placebo
at weeks 0, 4 and every 8 weeks, with placebo crossover to
guselkumab at week 24. Dactylitis was scored on a scale of
0–3 on each digit; enthesitis was assessed using the Leeds
Enthesitis Index (0–6). Other assessments included
American College of Rheumatology (ACR) and Psoriasis Area
and Severity Index responses.
Results Of 149 randomised patients, 107 patients had
enthesitis (mean score=2.7) and 81 patients had dactylitis
(mean dactylitis score=5.7) at baseline. Mean
improvements in enthesitis and dactylitis at week 24 were
greater in the guselkumab group versus placebo and
sustained through week 56. Similar results were observed
for the proportions of patients with resolution of enthesitis
and dactylitis. At week 56, mean improvements in enthesitis
and dactylitis among patients who switched from placebo to
guselkumab treatment were similar to those in the
guselkumab group. In the guselkumab group, ACR20
responders had greater improvements in enthesitis and
dactylitis versus non-responders (week 24).
Conclusions At week 24, the guselkumab group had
greater mean improvements in enthesitis and dactylitis and
greater proportions of patients with resolution of enthesitis
and dactylitis versus placebo. ACR20 response was
associated with improvements in enthesitis and dactylitis.
Trial registration number ClinicalTrials.gov:
NCT02319759.
URL: https://clinicaltrials.gov/ct2/show/NCT02319759;
Registered 18 December 2014.
INTRODUCTION
Psoriatic arthritis (PsA) is a progressive,
inflammatory spondyloarthritis that manifests
as musculoskeletal and skin disease. Patients
with PsA can experience peripheral arthritis,
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Key messages
What is already known about this subject?
► Guselkumab 100 mg was efficacious in reducing the
signs and symptoms of psoriatic arthritis (PsA) in
adult patients in a phase II study.
What does this study add?
► In this study, guselkumab was efficacious in treating
enthesitis and dactylitis among adults with PsA. Mean
improvements in enthesitis and dactylitis were greater
in the guselkumab group than in the placebo group at
week 24 and were observed as early as week 8 and
week 16, respectively. Greater proportions of
guselkumab-treated patients had resolution of
enthesitis and dactylitis when compared with placebo,
and these response rates were maintained over 1 year.
Improvements in enthesitis and dactylitis were
correlated with improvements in swollen and tender
joint counts. Improvements in enthesitis were also
correlated with SF-36 PCS and MCS scores, and
improvements in dactylitis were correlated with HAQ-
DI improvements at week 24.
How might this impact clinical practice?
► Improvements seen with guselkumab treatment in
enthesitis and dactylitis, which are an important
consideration for treatment of patients with PsA,
complement the improvements previously reported in
the articular signs and symptoms of PsA. The efficacy of
guselkumab on enthesitis and dactylitis in patients with
PsA will be further validated in ongoing phase III trials.
Psoriatic arthritis
Mease PJ, et al. RMD Open 2020;6:e001217. doi:10.1136/rmdopen-2020-001217 1
 o
n
 July 14, 2020 by guest. Protected by copyright.
http://rm
dopen.bmj.com/
R
M
D
 O
pen: first published as 10.1136/rm
dopen-2020-001217 on 13 July 2020. Downloaded from
 
axial disease, dactylitis and enthesitis as well as skin and
nail lesions.1 It has been estimated that more than half of
all patients with PsA experience dactylitis and/or
enthesitis.2 Enthesitis is a more common presentation in
PsA as compared with other forms of inflammatory arthri-
tis such as rheumatoid arthritis or ankylosing spondylitis.3
Enthesitis and dactylitis have considerable impact on
patients and are considered as important manifestations
for treatment goals. In an analysis from the CORRONA
Registry, PsA patients with dactylitis and enthesitis had
overall greater disease activity compared with patients
who did not have dactylitis and enthesitis, respectively,
and patients with enthesitis showed greater levels of func-
tional and work impairment compared with patients who
did not have enthesitis.4 Additionally, results from
a prospective cohort analysis of patients with PsA showed
that patients with enthesitis generally have worse radio-
graphic changes both in peripheral joints and the spine
than those without enthesitis.5 When developing the
composite measure of minimal disease activity (MDA)
for PsA, dactylitis and enthesitis were deemed to be criti-
cal aspects, while dactylitis was accounted for in the per-
ipheral tender and swollen joint counts, enthesitis scores
were added as a separate criterion in MDA.6 Of note,
enthesitis and dactylitis are separate disease domains con-
sidered in the treatment recommendations from the
Group for Research and Assessment of Psoriasis and Psor-
iatic Arthritis.7
Evidence from animal models and from human ima-
ging studies are contributing to the growing understand-
ing of dactylitis, enthesitis and their linkages and their
mechanisms, which may include common initiating fac-
tors such as skeletal mechanical strain.8 Interleukin-23
(IL-23) has been shown to be a key upstream regulator
in the pathogenesis of psoriasis9 and has been implicated
in the development of dactylitis and arthritis features of
PsA.10 Guselkumab, a monoclonal antibody targeting the
p19 subunit of IL-23, is approved for the treatment of
psoriasis.11 12 The efficacy and safety of guselkumab in
adult patients with active PsA was also evaluated in
a randomised, placebo-controlled, phase II trial.13
Patients treated with guselkumab 100 mg every 8 weeks
had significantly greater improvements in the signs and
symptoms of PsA, including dactylitis and enthesitis, com-
pared with placebo at week 24, and efficacy was main-
tained through 1 year in the guselkumab group.13 Here,
we report additional comprehensive analyses of the effect
of guselkumab on dactylitis and enthesitis in adults with
active PsA.
METHODS
Patients and study design
Patient eligibility criteria and details of the study
design have been previously described.13 Briefly,
adults (≥18 years) were eligible for enrollment in
this phase II, randomised, placebo-controlled trial if
they had a diagnosis of PsA for ≥6 months before the
first study drug administration and met the ClASsifica-
tion criteria for Psoriatic ARthritis (CASPAR)14 criteria
at screening. Patients had to have active PsA, defined as
≥3 swollen and ≥3 tender joints at screening and base-
line and a screening C reactive protein (CRP) level
≥0.3 mg/dL, despite current or previous therapy with
conventional synthetic disease-modifying anti-rheumatic
drugs, oral corticosteroids, and/or non-steroidal anti-
inflammatory drugs (NSAIDs). Up to 20% of the patient
population could have had previous treatment with one
anti-tumour necrosis factor (TNF) agent. Patients also
had to have ≥3% body surface area affected by plaque
psoriasis at screening and baseline.
Eligible patients were randomly assigned (2:1) to
receive subcutaneous injections of guselkumab
100 mg or placebo at weeks 0, 4 and every 8 weeks
through week 44. Patients in the placebo group crossed
over to receive guselkumab at weeks 24, 28 and every
8 weeks thereafter. At week 16, patients in both groups
who had less than 5% improvement in swollen and
tender joint counts were eligible for open-label early
escape and switch to ustekinumab, at the approved
dosage in the local country.
Assessments
The primary endpoint was the proportion of patients
achieving a 20% improvement in the American College
of Rheumatology criteria (ACR20 response) at week 24.
Severity of skin disease was evaluated using the Psoriasis
Area and Severity Index (PASI)15; the proportion of
patients achieving ≥75% improvement in PASI score was
determined. Dactylitis and enthesitis assessments were
performed at weeks 0, 4, 8, 16, 24, 28, 32, 44 and 56.
Dactylitis was assessed using a scoring system of 0–3
(0=absent, 1=mild, 2=moderate, 3=severe) based on swel-
ling and erythema for each digit, with a combined range
of 0–60.16 Enthesitis was evaluated using the Leeds Enthe-
sitis Index, which assesses tenderness in the left and right
lateral epicondyle, medial femoral condyle and Achilles
tendon insertion by applying enough pressure to blanch
the fingernail (total score 0–6).17 Overall, health-related
quality of life was assessed using the 36-item Short-form
Health Survey (SF-36) Physical and Mental Component
Summary (PCS/MCS) scores.
Statistical analysis
Changes in enthesitis and dactylitis scores and the pro-
portions of patients with complete resolution of enthesitis
or dactylitis (ie, score=0) were analysed only in patients
who had enthesitis or dactylitis, respectively, at baseline.
In addition, the presence of dactylitis at each digit (0–20)
was summarised. Missing data were imputed using last
observation carried forward through week 24. For
patients who met the early escape criteria at week 16,
the week-16 data were carried forward through week 24.
Data were summarised using descriptive statistics.
Between-treatment comparisons of change from baseline
in enthesitis score through week 24 were performed using
RMD Open
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analysis of covariance, and between-treatment compari-
sons of change from baseline in dactylitis score/the num-
ber of digits with dactylitis through week 24 were
performed using Wilcoxon rank-sum test. Between-
treatment comparisons of the proportions of patients
with complete resolution of dactylitis/enthesitis through
week 24 were performed using the Cochran–Mantel–
Haenszel test. In addition, treatment group comparisons
of the proportions of tender entheses (lateral epicondyle,
medial femoral condyle and Achilles tendon) at baseline
with resolution at week 24 were performed using the χ²
test. In this analysis, p values were not adjusted for multi-
plicity and are nominal.
Observed changes from baseline in dactylitis and enthe-
sitis scores at week 24 by ACR20 and ACR50, PASI 75,
PASI 90 and PASI 100 response at week 24 were sum-
marised, and p values were calculated using analysis of
covariance model among guselkumab-treated patients
who had enthesitis or dactylitis at baseline, respectively,
and did not discontinue or early escape prior to week 24.
Spearman correlation analyses were performed for
changes in dactylitis scores and enthesitis scores and
changes in ACR components (swollen (0–66) and tender
(0–68) joint counts, pain visual analog scale (VAS), Phy-
sician’s Global Assessment VAS, Patient’s Global Assess-
ment VAS, Health Assessment Questionnaire-Disability
Index (HAQ-DI), and CRP), SF-36 PCS and MCS scores,
and PASI score at week 24 among guselkumab-treated
patients who had enthesitis or dactylitis at baseline,
respectively, and did not discontinue or early escape
prior to week 24.
After week 24, observed data were reported with no
imputation for missing data, and patients who met the
early escape criteria or discontinued prior to week 24
were excluded from analyses. No formal hypothesis test-
ing was performed after week 24, when all patients were
receiving guselkumab.
RESULTS
Patient demographics and disease characteristics at baseline
The baseline demographic and disease characteristics of
the overall population have been previously described in
detail.13 A total of 149 patients from 34 sites in seven
countries were randomised to receive placebo (n=49) or
guselkumab (n=100).
At baseline, 107 patients (71.8%) had enthesitis, with
a mean enthesitis score of 2.7 (median=2.0); these
patients generally had higher mean numbers of swollen
joints and tender joints compared with patients who did
not have enthesitis at baseline. Prior medication use was
similar for patients with and without enthesitis, with the
exception of methotrexate (MTX), which was less com-
monly used by patients who had enthesitis (table 1). Of
Table 1 Baseline demographic and disease characteristics of patients with and without enthesitis
With enthesitis at baseline Without enthesitis at baseline
Placebo Guselkumab Total Placebo Guselkumab Total
Patients, n 31 76 107 18 24 42
Age, years 46.0 ± 12.7 48.0 ± 12.4 47.4 ± 12.5 41.0 ± 11.6 45.4 ± 14.2 43.5 ± 13.2
Male 14 (45.2) 35 (46.1) 49 (45.8) 10 (55.6) 27 (70.8) 27 (64.3)
Weight, kg 85.0 ± 16.5 85.6 ± 23.1 85.4 ± 21.3 88.6 ± 26.5 80.6 ± 14.6 84.0 ± 20.6
SJC (0–66) 12.4 ± 8.7 12.6 ± 7.3 12.5 ± 7.7 7.4 ± 2.9 9.8 ± 8.4 8.8 ± 6.7
TJC (0–68) 25.2 ± 12.5 22.7 ± 12.0 23.4 ± 12.1 11.3 ± 5.9 14.6 ± 10.7 13.2 ± 9.0
CRP, mg/dL 2.0 ± 2.5 1.9 ± 2.5 1.9 ± 2.5 1.5 ± 2.2 1.6 ± 2.2 1.6 ± 2.2
HAQ-DI 1.50 ± 0.44 1.48 ± 0.60 1.49 ± 0.56 1.06 ± 0.60 1.22 ± 0.66 1.15 ± 0.63
PsA duration, years 7.5 ± 7.7 7.0 ± 7.3 7.1 ± 7.4 5.9 ± 6.4 6.9 ± 7.2 6.5 ± 6.8
Patients with dactylitis 14 (45.2) 45 (59.2) 59 (55.1) 9 (50.0) 13 (54.2) 22 (52.4)
Dactylitis score 2.1 ± 3.3 4.1 ± 5.9 3.5 ± 5.4 1.4 ± 1.8 2.7 ± 4.7 2.2 ± 3.8
Patients with enthesitis 31 (100) 76 (100) 107 (100) 0 0 0
Enthesitis score 2.6 ± 1.5 2.7 ± 1.5 2.7 ± 1.5 – – –
BSA, % 12.8 ± 12.7 16.5 ± 15.2 15.5 ± 14.5 14.8 ± 12.5 19.5 ± 16.9 17.5 ± 15.2
PASI (0–72) 9.9 ± 8.5 12.0 ± 10.7 11.4 ± 10.1 9.9 ± 7.2 12.1 ± 10.2 11.1 ± 9.0
Previous anti-TNF therapy 2 (6.5) 8 (10.5) 10 (9.3) 2 (11.1) 2 (8.3) 4 (9.5)
Baseline medication use
MTX 7 (22.6) 34 (44.7) 41 (38.3) 12 (66.7) 13 (54.2) 25 (59.5)
Oral corticosteroids 4 (12.9) 10 (13.2) 14 (13.1) 4 (22.2) 2 (8.3) 6 (14.3)
NSAIDs 23 (74.2) 52 (68.4) 75 (70.1) 13 (72.2) 18 (75.0) 31 (73.8)
Data presented as n (%) or mean ± SD unless otherwise noted.
BSA, body surface area; CRP, C reactive protein; HAQ-DI, Health Assessment Questionnaire-Disability Index; MTX, methotrexate; NSAIDs,
non-steroidal anti-inflammatory drugs; PASI, Psoriasis Area and Severity Index; PsA, psoriatic arthritis; SJC, swollen joint count; TJC, tender
joint count; TNF, tumour necrosis factor.
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the patients with enthesitis at baseline, 51 (47.7%)
had enthesitis at the lateral epicondyle, 60 (56.1%)
had enthesitis at the medial femoral condyle, and 69
(64.5%) had enthesitis at the Achilles tendon
insertion.
At baseline, 81 patients (54.4%) had dactylitis with
amean dactylitis score of 5.7 (median=4.0); these patients
generally had higher mean numbers of swollen and ten-
der joints and higher CRP levels than did patients without
dactylitis at baseline. Prior use of anti-TNF agents, MTX
and NSAIDs was generally similar for patients with and
without dactylitis at baseline (table 2).
Changes in enthesitis
Among patients with enthesitis at baseline, the mean
reduction from baseline in enthesitis score was greater
in the guselkumab group compared with placebo at week
2413; with separation between the treatment groups
observed by week 8 (figure 1A). Mean improvement in
enthesitis score in the guselkumab group was maintained
through week 56 (figure 1B). In the placebo-crossover
group, notable improvements in the mean change from
baseline were observed 8 weeks after initiating guselku-
mab therapy at week 24 and were similar to those in the
guselkumab group at week 56 (figure 1B).
Among those with enthesitis at baseline, the proportion
of patients with resolution of enthesitis was also greater in
the guselkumab group compared with placebo (p<0.05)
at week 24 (figure 2A). In the guselkumab group, the
proportion of patients with resolution of enthesitis was
maintained through week 56. Among patients in the
placebo-crossover group, the proportion of patients
achieving resolution of enthesitis was similar to that in
the guselkumab group 8 weeks following crossover to
guselkumab therapy and maintained through week 56
(figure 2B). When evaluated by individual site (lateral
epicondyle, medial femoral condyle and Achilles ten-
don), improvements were seen both in upper limb and
lower limb sites at week 24 in those patients who had
tender entheses at those anatomical sites at baseline and
did not early escape (online supplementary figure 1).
Correlation and association of changes in enthesitis score with
improvements in joint, skin and quality of life measures
In the guselkumab group, the mean improvement in
enthesitis score was greater for patients who achieved
an ACR20 response at week 24 compared with ACR20
non-responders. A similar trend was also observed for
ACR50 response after adjusting for baseline factors,
while an association between enthesitis improvement
and skin response was not consistently seen with PASI
Table 2 Baseline demographic and disease characteristics of patients with and without dactylitis
With dactylitis at baseline Without dactylitis at baseline
Placebo Guselkumab Total Placebo Guselkumab Total
Patients, n 23 58 81 26 42 68
Age, years 37.8 ± 10.3 45.2 ± 13.3 43.1 ± 12.9 49.8 ± 11.5 50.5 ± 11.7 50.2 ± 11.5
Male 8 (34.8) 33 (56.9) 41 (50.6) 16 (61.5) 19 (45.2) 35 (51.5)
Weight, kg 86.1 ± 20.5 82.6 ± 19.0 83.6 ± 19.3 86.5 ± 21.0 86.8 ± 24.4 86.7 ± 23.0
SJC (0–66) 10.6 ± 6.1 14.0 ± 8.1 13.1 ± 7.7 10.5 ± 8.7 9.1 ± 5.7 9.6 ± 7.0
TJC (0–68) 22.5 ± 14.4 22.7 ± 11.7 22.6 ± 12.4 18.0 ± 10.3 18.0 ± 12.4 18.0 ± 11.6
CRP, mg/dL 1.9 ± 2.1 2.2 ± 2.7 2.1 ± 2.5 1.8 ± 2.6 1.3 ± 2.0 1.5 ± 2.3
HAQ-DI 1.36 ± 0.46 1.48 ± 0.59 1.44 ± 0.56 1.32 ± 0.61 1.34 ± 0.66 1.33 ± 0.64
PsA duration, years 4.7 ± 5.3 5.7 ± 5.6 5.4 ± 5.5 8.8 ± 8.2 8.7 ± 8.8 8.8 ± 8.5
Patients with dactylitis 23 (100) 58 (100) 81 (100) 0 0 0
Dactylitis score 3.9 ± 3.0 6.5 ± 6.2 5.7 ± 5.5 – – –
Patients with enthesitis 14 (60.9) 45 (77.6) 59 (72.8) 17 (65.4) 31 (73.8) 48 (70.6)
Enthesitis score 1.7 ± 1.8 2.0 ± 1.6 1.9 ± 1.7 1.7 ± 1.7 2.1 ± 2.0 1.9 ± 1.9
BSA, % 11.6 ± 9.8 18.0 ± 16.7 16.2 ± 15.3 15.3 ± 14.5 16.3 ± 14.0 15.9 ± 14.1
PASI (0–72) 9.6 ± 8.8 12.3 ± 10.8 11.6 ± 10.3 10.1 ± 7.3 11.7 ± 10.2 11.1 ± 9.2
Previous anti-TNF therapy 1 (4.3) 5 (8.6) 6 (7.4) 3 (11.5) 5 (11.9) 8 (11.8)
Baseline medication use
MTX 8 (34.8) 25 (43.1) 33 (40.7) 11 (42.3) 22 (52.4) 33 (48.5)
Oral corticosteroids 4 (17.4) 7 (12.1) 11 (13.6) 4 (15.4) 5 (11.9) 9 (13.2)
NSAIDs 16 (69.6) 38 (65.5) 54 (66.7) 20 (76.9) 32 (76.2) 52 (76.5)
Data presented as n (%) or mean ± SD unless otherwise noted.
BSA, body surface area; CRP, C reactive protein; HAQ-DI, Health Assessment Questionnaire-Disability Index; MTX, methotrexate; NSAIDs,
non-steroidal anti-inflammatory drugs; PASI, Psoriasis Area and Severity Index; PsA, psoriatic arthritis; SJC, swollen joint count; TJC, tender
joint count; TNF, tumour necrosis factor.
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75, PASI 90 and PASI 100 (figure 3A) or changes in PASI
score (table 3). Of note, among guselkumab-treated
patients, 66.7% (50/75) had improvement in enthesitis
score and achieved a PASI 75 response at week 24.
Improvements in enthesitis scores in the guselkumab
group were moderately correlated with changes from
Figure 1 Mean change from baseline in enthesitis score through week 24 (A) and week 56 (B) and mean change from baseline in
dactylitis score through week 24 (C) and week 56 (D). Through week 24, missing data and data for patients who entered early
escape were imputed using last observation carried forward (panels A and C); after week 24, no imputation was made for missing
data, observed data were used and patients who early escaped or discontinued prior to week 24 were not included in the analysis
(panels B and D). GUS, guselkumab; PBO, placebo.
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baseline in swollen and tender joint counts, Patient’s
Global Assessment, Physician’s Global Assessment and
SF-36 PCS and MCS scores (table 3).
Changes in dactylitis
Among patients with dactylitis at baseline, the mean
improvement from baseline in dactylitis score was greater
Figure 2 The proportion of patients with resolution of enthesitis through week 24 (A) and week 56 (B) and the proportion of
patients with resolution of dactylitis throughweek 24 (C) and week 56 (D). Throughweek 24, missing data and data for patients who
entered early escapewere imputed using last observation carried forward (panels A andC); after week 24, no imputation wasmade
for missing data, observed data were used, and patients who early escaped or discontinued prior to week 24 were not included in
the analysis (panels B and D). GUS, guselkumab; PBO, placebo.
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in the guselkumab group than in the placebo group
(p<0.01) at week 24 (figure 1C). Similar results were
observed for mean changes from baseline in the number
of digits with dactylitis in the guselkumab group compared
with placebo (−2.1 vs −0.2; p=0.003) at week 24. Mean
improvement in dactylitis score was maintained through
week 56 in the guselkumab group (figure 1D). In the
placebo-crossover group, noticeable improvements in the
mean dactylitis scores were observed 4 weeks after initiating
guselkumab therapy (figure 1D).
Among patients with dactylitis at baseline, greater pro-
portions of patients in the guselkumab group achieved
resolution of dactylitis at week 24 compared with those in
the placebo group (p<0.01; figure 2C). In the guselkumab
group, the response rate for resolution of dactylitis was
maintained throughweek 56. Among patients who crossed
over from placebo to guselkumab at week 24, the
proportion of patients achieving resolution of dactylitis
improved following initiation of guselkumab therapy and
was maintained through week 56 (figure 2D).
Correlation and association of changes in dactylitis score with
improvements in joint, skin and quality of life measures
Among patients in the guselkumab group, patients who
achieved an ACR20 or ACR50 response at week 24 had
greater mean improvements in dactylitis score compared
with non-responders (figure 3B). Mean changes in dacty-
litis score were similar regardless of PASI 75, PASI 90 or
PASI 100 response at week 24 and there was no correla-
tion between changes in dactylitis score and changes in
PASI score (table 3). Of note, 66.7% (38/57) of patients
treated with guselkumab had improvement in dactylitis
score and achieved a PASI 75 response at week 24.
Improvements in dactylitis score in the guselkumab
Figure 3 Mean changes from baseline to week 24 in enthesitis score (A) and dactylitis score (B) among ACR20, ACR50, PASI 75,
PASI 90, PASI 100 responders and non-responders in the guselkumab group. ACR 20/50, ≥20%/50% improvement in American
College of Rheumatology criteria; PASI 75/90/100, ≥75%/90%/100% in Psoriasis Area and Severity Index score. ACR, American
College of Rheumatology; PASI, Psoriasis Area and Severity Index.
Psoriatic arthritis
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group were correlated with improvements in swollen
and tender joint counts and HAQ-DI scores at week 24
(table 3). Forty-four patients treated with guselkumab
had enthesitis and dactylitis at baseline and available
data at week 24; of these, 32 patients had improvements
in both enthesitis and dactylitis scores.
DISCUSSION
Enthesitis and dactylitis are important clinical manifesta-
tions of PsA and can have substantial detrimental effects
on physical function and quality of life. Enthesitis is a key
component of developing dactylitis8 18 and, in a previous
study, digits with dactylitis had more radiographic joint
damage than those without dactylitis.19 To our knowl-
edge, this is the first study to report the effects of treat-
ment with a monoclonal antibody specific to the p19
subunit of IL-23 on enthesitis and dactylitis in patients
with PsA.
In this phase II study, patients who received guselku-
mab had greater improvements in enthesitis and dactyli-
tis scores through week 24, compared with placebo with
notable improvements occurring at weeks 8 and 16. The
mean changes in enthesitis and dactylitis scores were
maintained through week 56 for patients in the guselk-
umab group. Similar results were observed in the propor-
tions of patients who achieved resolution of enthesitis or
dactylitis for patients who were affected at baseline. These
improvements were sustained through 1 year.
The Achilles tendon and lateral epicondyle are among
the most commonly affected enthesitis sites in patients
with PsA and are often affected bilaterally.20 The involve-
ment of the Achilles tendon, in particular, can lead to
significant physical impairment and pain21 and is
a challenging aspect of treatment in patients with PsA.18
The guselkumab treatment group had improvement in
all sites evaluated for enthesitis including lateral epicon-
dyle, medial femoral condyle and Achilles tendon.
It is important to note, however, that clinical assessment
of peripheral enthesitis is challenging and may not relate
to other, more objective assessments, such as ultrasound
of the enthesis. It is also important to note that wide-
spread allodynia may be part of a chronic inflammatory
musculoskeletal disorder, and that when the inflamma-
tion is abrogated, by whatever means, the allodynia may
diminish.22 In practical terms, this may be reflected by
improvement in clinical enthesitis scores, independently
of any actual improvement in inflammation at the
enthesis.23
The IL-23/Th17 axis has been shown to be critical in
the pathogenesis of both enthesitis and dactylitis.9 In vivo
studies have shown that systemic exposure of IL-23 in
a murine model resulted in severe paw swelling as
a manifestation of entheseal inflammation.24 Addition-
ally, a recent analysis of entheses of normal human sub-
jects found resident myeloid cells capable of producing
IL-23.25 These mechanistic findings have been corrobo-
rated with clinical evidence. The results of the ECLIPSA
study suggest that enthesitis is sensitive to IL-12/23 p40
inhibition, with a greater proportion of ustekinumab-
treated patients having complete resolution of enthesitis
compared with those who received anti-TNF therapy.26
Furthermore, preliminary biomarker data from patients
in this guselkumab phase II study showed elevations of
serum IL-17A and IL-17F at baseline compared with
healthy controls, which decreased to levels similar to
healthy controls after 16 weeks of guselkumab
treatment.27 These results indicate that IL-23p19 subunit
inhibition is effective in resolving peripheral enthesitis.
Table 3 Correlations of changes from baseline in dactylitis and enthesitis scores with changes from baseline in other measures
of disease activity at week 24 for patients in the guselkumab group
Correlations with change
in enthesitis score at
week 24*
Correlations with change
in dactylitis score at week
24†
r value P value r value P value
Swollen joint count (0–66) 0.27 0.02 0.50 <0.0001
Tender joint count (0–68) 0.37 0.001 0.38 0.004
Patient’s assessment of pain (VAS, 0–100 mm) 0.13 0.28 0.08 0.53
Patient’s global assessment of disease activity (VAS, 0–100 mm) 0.32 0.005 0.20 0.14
Physician’s global assessment of disease activity (VAS, 0–100 mm) 0.47 <0.0001 0.10 0.47
HAQ-DI score (0–3) 0.13 0.28 0.33 0.01
CRP, mg/dL 0.11 0.33 0.13 0.34
SF-36 PCS −0.27 0.02 −0.22 0.09
SF-36 MCS −0.35 0.002 −0.21 0.12
PASI 0.18 0.13 0.01 0.95
*n=75.
†n=57.
CRP, C reactive protein; HAQ-DI, Health Assessment Questionnaire-Disability Index; PASI, Psoriasis area And Severity Index; SF-36MCS/PCS,
36-item Short-form Health Survey Mental/Physical Component Summary; VAS, visual analog scale.
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Guselkumab has been reported to significantly
improve joint and skin manifestations of PsA.13 In this
analysis, improvement in enthesitis was associated with
improvements in joint counts, ACR response, and qual-
ity of life as measured by SF-36, and improvement in
dactylitis was correlated with improvement in joint
counts, ACR response, and physical function as mea-
sured by HAQ-DI. These results suggest that guselkumab
is able to improve multiple domains of disease in
patients with PsA and adds to the evidence that enthesi-
tis and dactylitis resolution are important treatment
goals.
This was a relatively small, 1-year, phase II trial; how-
ever, multiple study sites were included from seven coun-
tries. The results reported here are limited by the
exploratory nature of these analyses and dactylitis and
tender/swollen joint assessments may be confounded.
Correlation analyses were also limited due to potential
non-linearity of underlying data of various scales used.
There is a need to better understand the impact of inhi-
biting the IL-23 pathway in axial polyenthesitis/osteitis of
ankylosing spondylitis; however, spondylitis was not
assessed in this study.
CONCLUSIONS
In conclusion, these findings, together with the results
previously reported,13 support the contention that IL-23
p19 subunit pathway antagonism is effective for resolving
dactylitis and peripheral enthesitis associated with PsA.
Further assessment on dactylitis, peripheral and axial
enthesitis will be conducted in the ongoing phase III
confirmatory studies.
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